Browse the evidence

Treatment of wild-type mice with linolenic acid reduced food intake and body mass.

Using linolenic acid may help reduce food intake and body mass in certain contexts.

Treatment with semaglutide was associated with a significant odds of NAION (OR, 3.92; 95% CI, 1.02-15.02).

Clinicians should monitor for NAION in patients treated with semaglutide.

Current evidence remains insufficient to establish definitive conclusions regarding the association of semaglutide with NAION.

Further research is needed to clarify the risk of NAION with semaglutide.

The article will review research pertaining to the risks of performing dynamic spinal flexion exercises.

The findings from this review may inform exercise performance guidelines.

The applicability of findings regarding spinal flexion exercises to exercise performance will be discussed.

Understanding the implications of spinal flexion exercise research can enhance program design.

Eccentric duration had no impact on rating of perceived exertion (RPE), range of motion (ROM), or barbell path.

Eccentric phase manipulation may not affect perceived exertion or movement mechanics.

There was no significant difference in detecting change in fat-free mass (FFM) at 12 and 32 weeks among underwater weighing, BIA, and skinfold measurements.

Different methods for measuring body composition can be used interchangeably without significant differences in outcomes.

The rationale for health promotion at the event was overly simplistic and ignored broader factors.

Health promotion strategies should consider a wider range of influencing factors beyond individual choices.

The screening criteria for sarcopenic obesity include BMI, waist circumference, calf circumference, the SARC-F, and the Finger Ring test.

These criteria can guide practitioners in screening for sarcopenic obesity.

Nonsurgical options for obesity treatment are limited.

Healthcare providers should be aware of the limited treatment options available for obesity.

Benefits of the intervention were not evident for those entering the trial with a history of cardiovascular disease.

Practitioners should consider individual health histories when recommending lifestyle interventions.

Consumption of both dietary plant and animal protein was not related to the risk of total CHD and HTN.

Neither plant nor animal protein intake is linked to increased risk of CHD or HTN.

The risk of CHD and HTN did not change significantly with increasing dietary total protein intake from 10% to 25% of total calorie intake.

Increasing total protein intake within this range does not affect CHD or HTN risk.

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

No significant association was found between dietary carbohydrate and CVD mortality (HR=1.02; 95% CI: 0.91, 1.14).

Dietary carbohydrate intake may not significantly impact CVD mortality, suggesting other factors may be more influential.

Obesity prevalence is projected to grow by 40% in the next decade.

Healthcare practitioners should prepare for increased obesity-related health issues.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

A higher state of energy flux may enhance the sensitivity between energy intake and expenditure.

Encouraging higher energy expenditure may improve clients' ability to manage their weight effectively.

There were no significant differences in mean values for %fat and fat-free mass between pretesting, post-testing, and delta data.

The lack of significant differences suggests consistency in body composition measurements.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

Further studies are needed to better evaluate and refine the efficacy of technology-based WLMIs.

Ongoing research is essential for improving the effectiveness of technology-based weight loss interventions.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.